Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CP-4126 in advanced pancreatic cancer
2007-007476-42Phase 2Terminated
- Sponsor
- Clavis Pharma
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in pancreatic cancer (PC), sponsored by Clavis Pharma. Primary endpoints: Overall survival and Association between hENT1 expression and survival. Started Nov 2008; status: terminated.
02
Drugs
gemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2007-007476-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007476-42.